Please contact Oryn if you wish to have a copy of the presentation given by Dr. Michael Selsted, Chief Scientific Officer of Oryn Therapeutics.
- USC Press release: Oryn and University of Southern California scientists report on first-in-class macrocyclic peptide therapeutic for treatment of rheumatoid arthritis November 30, 2017
- PLoS ONE publication: Oryn and USC collaborators publish in PLoS ONE the application of Orynotides for treatment of evolving and severe rheumatoid arthritis November 29, 2017
- Oryn selected to present at 2016 BIO International Convention June 7, 2016
- Oryn Therapeutics and Keck Medicine of USC RECEIVE $5.3 M NIH award May 17, 2016
- Oryn therapeutics secures $3,000,000 of angel investment September 2, 2015